These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10295911)

  • 1. FDA action spurs change in groups' drug programs.
    Perry PA
    Hosp Mater Manage; 1989 Nov; 14(11):1, 13-4. PubMed ID: 10295911
    [No Abstract]   [Full Text] [Related]  

  • 2. Generics still a favorite Rx for savings.
    Wagner M
    Mod Healthc; 1990 May; 20(21):26-8, 30, 32-3. PubMed ID: 10104890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Groups adapt to generic drug probe with buying strategies.
    Perry PA
    Hosp Mater Manage; 1989 Oct; 14(10):1, 14-5. PubMed ID: 10324694
    [No Abstract]   [Full Text] [Related]  

  • 4. LyphoMed hopes to put troubles behind it.
    Wagner M
    Mod Healthc; 1989 Jan; 19(2):57. PubMed ID: 10291291
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug purchasing.
    Mehl B
    Hosp Pharm; 1988 Mar; 23(3):283-6. PubMed ID: 10318047
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA takes action against firms in scandal over generic products.
    Pollner F
    Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of drug industry marketing practices on formularies questioned by federal agencies.
    Gatty B
    Hosp Formul; 1994 Nov; 29(11):786, 785. PubMed ID: 10138576
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug purchasing considerations.
    Mehl B
    Hosp Pharm; 1988 Oct; 23(10):913, 916-7. PubMed ID: 10290113
    [No Abstract]   [Full Text] [Related]  

  • 9. Watching Washington. Interview by David Cassak.
    Wilbur B
    Surg Bus; 1980 Aug; 43(8):42-5, 48-9. PubMed ID: 10248427
    [No Abstract]   [Full Text] [Related]  

  • 10. LyphoMed, FDA reach agreement.
    Wagner M
    Mod Healthc; 1988 May; 18(22):6. PubMed ID: 10287683
    [No Abstract]   [Full Text] [Related]  

  • 11. Upjohn pharmacist reimbursement programs halted by FDA.
    Am J Hosp Pharm; 1993 Feb; 50(2):200, 205. PubMed ID: 8480773
    [No Abstract]   [Full Text] [Related]  

  • 12. Generic drug purchasing.
    Mehl B
    Hosp Pharm; 1988 Feb; 23(2):162-4 contd. PubMed ID: 10286432
    [No Abstract]   [Full Text] [Related]  

  • 13. Hospitals vigilant for quality in pharmacy.
    Perry PA
    Hosp Mater Manage; 1989 Dec; 14(12):1-2. PubMed ID: 10296163
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits and liabilities of generic prescribing.
    Lee AM
    W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384
    [No Abstract]   [Full Text] [Related]  

  • 15. Formulary for trouble. Alliance, data firm in duel on drug-buying information.
    Hensley S
    Mod Healthc; 1998 Mar; 28(10):26-7. PubMed ID: 10177178
    [No Abstract]   [Full Text] [Related]  

  • 16. How to crack the $2 billion hospital market for pharmaceuticals.
    Zellmer WA
    Med Mark Media; 1981 May; 16(5):16, 24. PubMed ID: 10251527
    [No Abstract]   [Full Text] [Related]  

  • 17. New York State and drug lists: a history of confusion.
    Stetler CJ
    Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract]   [Full Text] [Related]  

  • 18. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives. FDA scandal: white hats, black hats, gray areas.
    Wiener JO
    Faulkner Grays Med Health; 1989 Dec; 43(48):suppl 6 p.. PubMed ID: 10296081
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic drug prices may rise 8-10%.
    Hosp Mater Manage; 1991 Feb; 16(2):1, 8-9. PubMed ID: 10109544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.